Pandion Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Pandion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PAND

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. (NASDAQ: PAND) to Merck is fair to Pandion shareholders.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, February 25, 2021
Information
Tags: 
Legal, Professional services, Articles, Legal entities, Pandion, Limited liability partnership, Securities fraud, Shareholder, Business, Organizations
Geotags: 
United States, NEW YORK
⚠generated by AI ↴
Summary
Key Points: 
  • Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. (NASDAQ: PAND) to Merck is fair to Pandion shareholders.
  • Under the terms of the agreement, Pandion shareholders will receive $60.00 per share in cash.
  • On behalf of Pandion shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.


Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. (NASDAQ: PAND) to Merck is fair to Pandion shareholders. Under the terms of the agreement, Pandion shareholders will receive $60.00 per share in cash.

Halper Sadeh encourages Pandion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

The investigation concerns whether Pandion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Pandion shareholders; (2) determine whether Merck is underpaying for Pandion; and (3) disclose all material information necessary for Pandion shareholders to adequately assess and value the merger consideration. On behalf of Pandion shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Pandion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright: 
Copyright Business Wire 2021